Clinical Trial

A Study of KM501 in Patients With Solid Tumors

Name: A Study of KM501 in Patients With Solid Tumors — clinical trial record (NCT05804864)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2

Trial Details

NCT Number	NCT05804864
Lead Sponsor	Xuanzhu Biopharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	96 participants
Start Date	2023-04
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2023-04-07